Generic Drug Development CDMO

Peptide CDMO Strategy United States vs. Overseas Peptide CDMOs: Should You Reshore Your Supply Chain? By Anusha Sinha • August […]

Introduction A Biosimilar CDMO in United States plays a critical role in achieving analytical comparability and regulatory acceptance by applying

Introduction Partnering with a specialized biosimilar CDMO in Canada allows biopharmaceutical companies to address the complex technical, analytical, and regulatory

Introduction Biotechnology companies increasingly collaborate with a Peptide CDMO in United states to establish dependable domestic supply networks, address sophisticated

Introduction A Peptide CDMO in Canada offers the specialized synthetic chemistry expertise, cGMP-compliant manufacturing capabilities, and comprehensive orthogonal analytical testing

Introduction The FDA’s Product-Specific Guidance for Tirzepatide outlines the regulatory, analytical, formulation, and drug-device combination product requirements that generic manufacturers

Introduction The decision to adopt a consolidated or split Drug Substance vs Drug Product CDMO model plays a pivotal role

Introduction Obtaining approval for an Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) requires manufacturers